Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis

被引：0
|
作者：
Szuber, Natasha [1 ]
Lasho, Terra L. [1 ]
Finke, Christy [1 ]
Hanson, Curtis A. [2 ]
Ketterling, Rhett P. [3 ]
Pardanani, Animesh [1 ]
Gangat, Naseema [1 ]
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Div Hematopathol, Rochester, MN USA
[3] Mayo Clin, Div Lab Genet & Genom, Rochester, MN USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117458
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1767
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis
    Natasha Szuber
    Terra L. Lasho
    Christy Finke
    Curtis A. Hanson
    Rhett P. Ketterling
    Animesh Pardanani
    Naseema Gangat
    Ayalew Tefferi
    Leukemia, 2019, 33 : 780 - 785
  • [2] Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis
    Szuber, Natasha
    Lasho, Terra L.
    Finke, Christy
    Hanson, Curtis A.
    Ketterling, Rhett P.
    Pardanani, Animesh
    Gangat, Naseema
    Tefferi, Ayalew
    LEUKEMIA, 2019, 33 (03) : 780 - 785
  • [3] Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey
    Murton, Alexandra
    Forsyth, Cecily
    Ross, David M.
    Grigg, Andrew
    LEUKEMIA & LYMPHOMA, 2023, 64 (12) : 2018 - 2025
  • [4] Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis
    Kourie, Hampig Raphael
    Ameye, Lieveke
    Paesmans, Marianne
    Bron, Dominique
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (05): : 264 - 268
  • [5] Long-term outcome of pomalidomide therapy in myelofibrosis
    Begna, Kebede H.
    Pardanani, Animesh
    Mesa, Ruben
    Litzow, Mark R.
    Hogan, William J.
    Hanson, Curtis A.
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 66 - 68
  • [6] Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
    Tefferi, Ayalew
    Litzow, Mark R.
    Pardanani, Animesh
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15): : 1455 - 1457
  • [7] Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
    Tefferi, Ayalew
    Begna, Kebede
    Hogan, William J.
    Litzow, Mark R.
    Hanson, Curtis A.
    Pardanani, Animesh
    BLOOD, 2011, 118 (21) : 764 - 764
  • [8] The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or "type 1-like" Calreticulin Variants
    Tefferi, Ayalew
    Lasho, Terra L.
    Tischer, Alexander
    Wassie, Emnet A.
    Finke, Christy
    Belachew, Alem A.
    Ketterling, Rhett
    Hanson, Curtis A.
    Pardanani, Animesh
    BLOOD, 2014, 124 (21)
  • [9] Long-term outcome of monoclonal (type 1) cryoglobulinemia
    Neel, Antoine
    Perrin, Francois
    Decaux, Olivier
    Dejoie, Thomas
    Tessoulin, Benoit
    Halliez, Maxime
    Mahe, Beatrice
    Lamy, Thierry
    Fakhouri, Fadi
    Jego, Patrick
    Agard, Christian
    Vigneau, Cecile
    Guenet, Lucienne
    Grosbois, Bernard
    Moreau, Philippe
    Hamidou, Mohamed
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (02) : 156 - 161
  • [10] LONG-TERM OUTCOME OF ALLOGENEIC TRANSPLANTATION IN PRIMARY AND SECONDARY MYELOFIBROSIS
    Zavrelova, Alzbeta
    Visek, Benjamin
    Lanska, Miriam
    Zak, Pavel
    Lukesova, Petra
    Radocha, Jakub
    BONE MARROW TRANSPLANTATION, 2024, 59 : 534 - 534
12345